Douglas W. House on Muck Rack

Douglas W. House

New York
As seen in: Archives of Disease in Childhood, Seeking Alpha, HuffPost UK, Science Magazine, citybizlist: Washington DC, citybizlist: Baltimore, Daily Business
Healthcare Investor
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Douglas W.

Contact Douglas W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PayPal Community

|
By Douglas W. House
| paypal-community.com
I received two Zettle card readers last week that both do not work, but show a Security Alert " the security sensor has been activated, and the device is now locked. Please call Zettle Customer Service." I have called them four times in the last 8 days, but they seem unable/unwilling to help. The only answer I get is that this has been escalted to Tech Support who has not come back yet.
Open in Who Shared View Duplicates (2) Issue with article?

Galapagos advances mid-stage study of kidney disease candidate (NASDAQ:GLPG)

|
By Douglas W. House
| Seeking Alpha
Dosing is underway in a 60-subject Phase 2 clinical trial, MANGROVE, evaluating Galapagos NV's (NASDAQ:GLPG) GLPG2737 in patients with autosomal dominant polycystic kidney disease. The primary efficacy endpoint is the mean percent change from baseline in height-adjusted total kidney volume at week 52. The estimated primary completion date is November 2022. GLPG2737 inhibits a protein called cystic fibrosis transmembrane conductance regulator (CFTR).
Open in Who Shared Issue with article?

Reata Pharma launches 2M-share stock offering (NASDAQ:RETA)

|
By Douglas W. House
| Seeking Alpha
Reata Pharmaceuticals (NASDAQ:RETA) commences a public offering of 2M shares of common stock. Price and terms have yet to be announced.
Open in Who Shared Issue with article?
See all 24,234 licensed articles (24,236 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified